论文部分内容阅读
美国食品和药品监督管理局4月24日批准了首个用于治疗罕见代谢性 疾病法布里病(酰基鞘氨醇己三糖苷酶缺乏症)的药物Fabrazyme。 Fabrazyme(agalsidase beta)是一种人工重组的酰基鞘氨醇己三糖苷酶。患有法布里病的患者机体不能制造这
On April 24, the U.S. Food and Drug Administration approved the first Fabrazyme, a drug used to treat Fabry disease (acyl sphingosine hexosaccharidase deficiency), a rare metabolic disease. Fabrazyme (agalsidase beta) is an artificially recombinant acyl sphingosine hexotriosidase. Patients with Fabry disease can not make this body